CD37 and primary cutaneous T-cell non-Hodgkin lymphoma: Given that most previous studies assess CD37 expression via immunostaining in tissue samples, further investigations should examine CD37 levels in peripheral blood in CTCL patients as CAR-T infusion would easily access the circulating malignant T cell population first.